Therefore, PHDi-based molecular therapies for IBD are being researched on the basis of inhibitors of prolyl hydroxylase (PHI, PHDi) of the co-substrate 2-oxoglutarate as controlling the expression of HIF-1α [120]. The gene discussed is HIF1A; the disease is inflammatory bowel disease.